Targeted Therapy (Antibody)
16 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Antibody) (14)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Cetuximab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Cetuximab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Aflibercept |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Aflibercept
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Bevacizumab |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Bevacizumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Brolucizumab (Onc Adjacent) |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Brolucizumab (Onc Adjacent)
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Dinutuximab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Dinutuximab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Matuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Matuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Mifamurtide |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Mifamurtide
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Naxitamab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Naxitamab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Necitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Necitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Nimotuzumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Nimotuzumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Olaratumab |
PDGFR / GD2 Targeting Agent | Solid Tumour (Sarcoma/Neuroblastoma) | ||
|
Molecule
Olaratumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
||||
Panitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Panitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
CetuximabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
AfliberceptTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
BevacizumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
Brolucizumab (Onc Adjacent)Targeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
DinutuximabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
MatuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
MifamurtideTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
NaxitamabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
NecitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
NimotuzumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
OlaratumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism
PDGFR / GD2 Targeting Agent |
|
PanitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|